Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA, USA.
Cancer J. 2011 Nov-Dec;17(6):429-37. doi: 10.1097/PPO.0b013e31823b042c.
Clinical outcomes in prostate cancer are heterogeneous, and given the high prevalence of the disease, there is a pressing need to identify clinically useful markers of prognosis. Many clinical, pathological, molecular, and genetic factors have been investigated in this capacity, although relatively few are routinely used. With a growing understanding of the molecular pathogenesis of prostate cancer, there is the potential that the next generation of makers will prove sufficiently robust to guide the optimal management of men with prostate cancer. Here, we review the various clinical and molecular prognostic determinants in prostate cancer.
前列腺癌的临床结果存在异质性，鉴于该疾病的高发病率，迫切需要确定具有临床应用价值的预后标志物。许多临床、病理、分子和遗传因素都在这方面进行了研究，尽管相对较少的因素被常规使用。随着对前列腺癌分子发病机制的深入了解，下一代标志物有可能具有足够的稳健性，从而指导前列腺癌患者的最佳管理。在这里，我们回顾了前列腺癌的各种临床和分子预后决定因素。
